The problem
Biomimicry sits in an awkward spot. The science is beautiful, the demos look great, but the path from laboratory novelty to commercially viable product is full of dead ends. Investors who can spot the difference early have an edge, and most do not have a framework for it.
My contribution
- Evaluated investment criteria across a portfolio of biomimicry-tagged startups, building toward a repeatable assessment framework
- Built comparative frameworks for assessing commercialization readiness on technical and market dimensions
- Synthesized findings across biology, engineering, and finance research streams into a single investor-facing view
- Worked alongside biology and engineering researchers. Economics in the same room as field science
The headline insight: the most fundable biomimicry ventures were rarely the ones with the most dramatic science. They were the ones whose teams could explain, in two sentences, exactly which existing market they would replace and how the unit economics worked at scale.